Q-omics provides the consensus-scored TNFRSF1B profile across patient tissues and cancer cell-line models. TNFRSF1B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TNFRSF1B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TNFRSF1B protein abundance shows 26,615 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where TNFRSF1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF1B survival associations across molecular data types. TNFRSF1B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF1B RNA expression–survival associations across cancer types. High TNFRSF1B expression shows unfavorable associations in UVM, THYM and LAML, but favorable associations in HNSC, SKCM and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TNFRSF1B RNA expression.
This table summarizes TNFRSF1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF1B shows lower tumor expression in UCEC, LUSC and LUAD and higher tumor expression in KIRC, THCA and STAD. The KIRC box plot shows higher TNFRSF1B RNA expression in tumor versus normal tissue (log2 FC = +1.775, t-test p < 0.001).
This table shows molecular features associated with TNFRSF1B in patient tissues and cancer cell lines. In patient samples, TNFRSF1B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
